C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016', provides in depth analysis on C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted pipeline therapeutics. 

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) 
- The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Overview 10
Therapeutics Development 11
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Stage of Development 11
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Therapy Area 12
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Indication 13
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Companies 17
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Universities/Institutes 21
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development 30
AdAlta Pty Ltd. 30
Ambrx, Inc. 31
BioLineRx, Ltd. 32
Bristol-Myers Squibb Company 33
Eli Lilly and Company 34
Globavir Biosciences, Inc. 35
GlycoMimetics, Inc. 36
Juventas Therapeutics, Inc. 37
Pharis Biotec GmbH 38
Polyphor Ltd. 39
TaiGen Biotechnology Co., Ltd. 40
Upsher-Smith Laboratories, Inc. 41
X4 Pharmaceuticals, Inc. 42
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles 43
AD-114 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ALB-408 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
AM-3114 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
balixafortide - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
BL-8040 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
burixafor - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
GBV-4086 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
GMI-1359 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
HPH-112 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
HPH-196 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
HPH-211 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
hz-515H7 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
JVS-100 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
LY-2510924 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
POL-5551 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Protein to Agonize CXCR4 for Inflammation - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
PTX-9908 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Q-122 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Recombinant Proteins to Antagonize CXCR4 for Oncology and Autoimmune Disorders - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
ulocuplumab - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
USL-311 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
X-4P001 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
X-4P002 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Projects 89
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products 94
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Featured News & Press Releases 95
Oct 14, 2016: AdAlta update on Orphan Drug Designation application for lead drug targeting idiopathic pulmonary fibrosis 95
Oct 05, 2016: BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting 95
Sep 27, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1b Study of X4P-001 in Patients with Resectable Stage III and Stage IV Melanoma 96
Sep 20, 2016: BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA(pembrolizumab) for Treatment of Pancreatic Cancer 96
Sep 12, 2016: AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate 97
Sep 08, 2016: BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference 98
Sep 06, 2016: GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 99
Jun 28, 2016: BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA (pembrolizumab) for Treatment of Pancreatic Cancer 99
May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359 100
May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences 101
May 16, 2016: Upsher-Smith Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311 101
May 09, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 102
Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 102
Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting 103
Mar 29, 2016: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML 104
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Pipeline by AdAlta Pty Ltd., H2 2016 30
Pipeline by Ambrx, Inc., H2 2016 31
Pipeline by BioLineRx, Ltd., H2 2016 32
Pipeline by Bristol-Myers Squibb Company, H2 2016 33
Pipeline by Eli Lilly and Company, H2 2016 34
Pipeline by Globavir Biosciences, Inc., H2 2016 35
Pipeline by GlycoMimetics, Inc., H2 2016 36
Pipeline by Juventas Therapeutics, Inc., H2 2016 37
Pipeline by Pharis Biotec GmbH, H2 2016 38
Pipeline by Polyphor Ltd., H2 2016 39
Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 40
Pipeline by Upsher-Smith Laboratories, Inc., H2 2016 41
Pipeline by X4 Pharmaceuticals, Inc., H2 2016 42
Dormant Projects, H2 2016 89
Dormant Projects (Contd..1), H2 2016 90
Dormant Projects (Contd..2), H2 2016 91
Dormant Projects (Contd..3), H2 2016 92
Dormant Projects (Contd..4), H2 2016 93
Discontinued Products, H2 2016 94